



THE
BLADDER CANCER
COMPANY™

Photocure ASA – New share capital registered

Oslo, Norway, 28 April 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,179,638 shares at a subscription price of NOK 65.50 per share, raising gross proceeds of approximately NOK 143 million in a private placement (the "Private Placement").

The share capital increase pertaining to the issuance of the 2,179,638 new shares has now been registered with the Norwegian Register of Business Enterprises. The Company's new registered share capital is 11,988,012.50, divided into 23,976,025 shares, each with a par value of NOK 0.50 per share. Each share represents one vote in the Company's general meeting.

For further information, please contact:

Photocure ASA

Dan Schneider
President and CEO
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA

Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (OSE: PHO). The US headquarters for Photocure Inc., are in Princeton, New Jersey. For more information, please visit us at www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.